Trends in Conventional Heart Failure Therapy in a Real-World Multinational ATTR-CA Cohort.

ABSTRACT:

Background

Conventional HF treatment in transthyretin cardiac amyloidosis (ATTR-CA) resulting in restrictive cardiomyopathy is debated due to absent trial evidence in this specific sub-population of heart failure (HF) patients. Current European Society of Cardiology guidelines recommend the use of diuretics and mineralocorticoid receptor antagonists (MRAs). However, beta-blockers (BBs) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARBs) are often discontinued due to hypotension or bradycardia. This study assesses real-world HF treatment patterns and their impact on survival in a multinational ATTR-CA cohort.

Methods

A retrospective analysis of 794 ATTR-CA patients examined baseline BB, ACEi/ARB, and MRA prescriptions. The cohort was divi

SUBMITTER: van der Geest EH 

PROVIDER: S-EPMC12565287 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature